New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

  • Symtuza protease inhibitor regimen maintains viral suppression for a year

    People who switched from a multi-pill antiretroviral regimen to the first one-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to a report at the IDWeek 2017 conference last week in San Diego. On ...

    13 October 2017 | Liz Highleyman
  • Long-acting monoclonal antibody effective against multidrug-resistant HIV

    Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference ...

    12 October 2017 | Liz Highleyman
  • Maraviroc matches boosted protease inhibitor treatment over 96 weeks

    Treatment with maraviroc (Celsentri/Selzentry) is associated with durable HIV suppression and a favourable lipid profile, investigators report in HIV Medicine. The 96-week randomised study compared the safety and efficacy of antiretroviral regimens based on maraviroc to ...

    11 September 2017 | Michael Carter
  • Boosted darunavir plus lamivudine matches three-drug regimen

    A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results of the ANDES study presented last month by Professor Pedro Cahn at the 9th IAS Conference ...

    08 August 2017 | Keith Alcorn
  • VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment

    A broadly neutralising antibody modestly delayed the resurgence of viral replication following interruption of antiretroviral therapy (ART) started during very early infection, but all study participants ultimately experienced viral rebound, according to results presented last week at the 9th ...

    02 August 2017 | Liz Highleyman
  • Long-acting NRTI shows promise for HIV treatment and PrEP

    A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for seven days in an early clinical trial, and the drug also appears to protect monkeys from rectal infection with an HIV-like virus, ...

    02 August 2017 | Liz Highleyman
  • First protease inhibitor combination pill maintains viral suppression

    The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report at the 9th International AIDS Society ...

    01 August 2017 | Liz Highleyman
  • Doravirine combination pill looks good for initial HIV treatment

    A single-tablet regimen containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine reduced HIV viral load as much as an efavirenz-based co-formulation, but it had a more favourable side-effect profile, according to results from the DRIVE-AHEAD study presentation this ...

    27 July 2017 | Liz Highleyman
  • New integrase inhibitor bictegravir works well for first-line HIV treatment

    A single-tablet regimen containing the experimental integrase inhibitor bictegravir was as effective as two widely used approved regimens for first-line therapy in a pair of phase 3 clinical trials, according to presentations at the 9th International AIDS Society Conference on ...

    25 July 2017 | Liz Highleyman
  • Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks

    Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable viral load, according to the latest results from the LATTE-2 trial, presented ...

    24 July 2017 | Liz Highleyman
More news

New and experimental HIV treatments news selected from other sources

More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.